October 24, 2013 I La Merie published in February 2007 for the first time a compilation of the annual sales of therapeutic proteins and antibodies. Since then, we released every year our list of TOP selling antibodies and proteins. You can find these annual reports published in our weekly newsletter R&D Pipeline News as a special edition in our online portal www.pipelinereview.com under FREE Reports.
We thought you might find it useful to have a look how annual sales of antibodies and proteins developed since 2006. We first prepared a table with the data for antibodies and found an amazing average/continuous annual growth rate of 18.9 % from 2006 to 2012. You can download the data at: http://pipelinereview.com/index.php/download?path=antibody%20sales%202006-2012.pdf
Or go to the menu FREE Reports / FREE Downloads at www.pipelinereview.com
Last year, i.e. 2012, antibody sales summed up US$ 64.6 bln and for the first time were higher than those of recombinant protein therapeutics. Please bear in mind minor errors in accuracy of the data due to currency exchange influences and incomplete publication of some data. But the overall picture is clear: antibodies sell well! And it is not only cancer and anti-TNF antibodies which make out of most of antibody sales. New antibodies are have emerged recently and are gaining in market shares. It can be expected that they will compensate for potential future losses of leading antibodies when biosimilar antibodies come up.
October 17, 2013 I Undoubtedly, antibodies are a hot area for biotech and pharma companies. Development of antibody therapeutics not only seems to have a lower attrition rate than that of small molecules (at least for toxicity reasons), but antibody products are extremely commercially successful. No wonder, that many companies are „jumping on the wagon" of antibodies. However, only a fraction of the companies is working on antibody molecules directed against new targets. Many, if not the majority is focused on improving antibodies directed against validated and commercially successful targets or directly developing biosimilar versions. Risk aversion cannot be the only reason, but availability of new targets for antibodies seems to be a major bottleneck for industry.
One reason might be that target discovery so far has been focused on extracellular targets (proteins, carbohydrates, glycolipids), because intracellular targets are „not accessable" for antibodies. However, intracellular tumor-associated proteins make out more than 80% of potential cancer drug targets. One company recently has raised considerable interest when it closed within a short periof of time two significant deals with Big Pharma/Biotech companies for intracellular targets and T-cell receptor (TCR) based therapeutics in the field of cancer and viral diseases. This seems to be a kind of proof-of-concept for the attractiveness of the T-Cell Receptor for biopharmaceutical industry.
In light of the potential breakthrough character of the TCR technology, La Merie Publishing has performed a comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective. The report can be found in our online store at http://pipelinereview.com/index.php/therapeuticarea/oncology/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry-detail .
October 8, 2013 I The association of America’s biopharmaceutical companies (the Pharmaceutical Research and Manufacturers of America: PhRMA) recently released the report „Medicines in Development for Vaccines„. The report states that US companies are developing 271 vaccines in clinical stages to prevent or treat a variety of diseases including allergy, neurological diseases, cancer, infectious diseases and some others. The vast majority of vaccines is being developed for infections diseases (51%) followed by cancer vaccines (37%). Among the infectious disease vaccines are e.g. HIV, influneza, hepatitis C virus vaccines, but also vaccines against meningitis, Dengue virus, malaria, cytomegalovirus, herpes simplex virus and many more. The report includes an introduction into and overview of the vaccines field. It can be downloaded at the PhRMA site at http://phrma.org/sites/default/files/pdf/Vaccines_2013.pdf